The decade-long journey for a promising Duchenne muscular dystrophy treatment has reached a devastating conclusion, as PTC Therapeutics has officially withdrawn its application for Translarna from the U.S. market, marking the end of a contentious and ultimately unsuccessful bid for regulatory
As Costa Rican health officials monitor the nation's respiratory illness landscape, data from the Ministry of Health reveals a clear and pressing public health concern: Influenza A has firmly established itself as the most dominant circulating virus, outpacing both rhinovirus and COVID-19. In the
The loss of an adult tooth has long been considered a permanent event, a problem addressed only by synthetic replacements like dentures or implants that, while functional, are not a true biological restoration. However, a revolutionary wave of research emerging from Japan is challenging this
A recent comprehensive investigation by the Centers for Disease Control and Prevention (CDC) has brought a critical public health challenge into sharp focus, identifying extraintestinal invasive Escherichia coli as the foremost cause of sepsis that begins outside of a hospital setting. This
The American biomedical research landscape has emerged into 2026 bearing the deep and complex scars of a profoundly turbulent year, navigating a delicate balance between a renewed sense of financial security and a pervasive anxiety over the integrity of its foundational institutions. Following a
BioMarin Pharmaceutical is currently navigating a complex financial landscape as it prepares to release its financial results for the fourth quarter of 2025, presenting a puzzling scenario for the investment community. The prevailing consensus suggests a significant year-over-year decline in the
